JPRN-jRCT2080223271已完成3 期
Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis
ASAHI KASEI PHARMA CORPORATIO0 个研究点目标入组 74 人开始时间: 2016年7月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Main Inclusion Criteria
- •Patients diagnosed with AE-IPF
排除标准
- •Main Exclusion Criteria
- •[1]Have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding (continued hematemesis, bloody discharge, gastrointestinal ulcer-induced hemorrhage)
- •[2]Have a history of cerebrovascular disorder (e.g., cerebral hemorrhage or cerebral infarction) within 52 weeks (364 days) before informed consent
- •[3]Patients who are pregnant or nursing, or who may be pregnant
- •[4]Have a history of hypersensitivity for investigational product
研究者
相似试验
已完成
3 期
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections (Multicenter double-blind randomized parallel group comparative study with heparin sodium as control drug)Disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infectionsJPRN-C000000327Asahi Kasei Pharma Corporation220
未知
3 期
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infectionsDisseminated intravascular coagulation (DIC)JPRN-jRCT2080220059ASAHIKASEI PHARMA CORPORATIO
未知
4 期
A postmarketing clinical study on ART-123 in patients with DIC caused by solid tumorDisseminated intravascular coagulation (DIC) directly caused by solid tumorJPRN-jRCT1080220847ASAHI KASEI PHARMA CORPORATIO100
已完成
3 期
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT02739165Asahi Kasei Pharma Corporation74
已完成
2 期
Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon CancerPostoperative Stage II/III Colon CancerNCT02792842Asahi Kasei Pharma Corporation79